# Meningococcal Meningitis

> The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.

Source: https://medova.health/en/knowledge/diseases/meningococcal-meningitis · Language: en

## Overview

Bacterial meningitis and septicemia caused by Neisseria meningitidis. Rapidly fatal without treatment; vaccination required for Hajj pilgrims and recommended for Africa's meningitis belt.

## Medical Information

- ICD-10: A39.0
- ICD-11: 1C18.0
- Causative Agent: bacteria
- Severity: Critical
- Incubation Period: 2–10 days
- Mortality Rate: 0.15%
- Vaccine available: Yes

## Symptoms

- Confusion (40%)
- Fever (90%)
- High fever (70%)
- Irritability (70%)
- Neck stiffness (75%)
- Petechiae (65%)
- Photophobia (60%)
- Rash (70%)
- Severe headache (85%)
- Vomiting (65%)
- Altered consciousness (30%)
- Bruising (25%)
- Chills (55%)
- Dehydration (35%)
- Fatigue (50%)
- Hemorrhage (15%)
- Hypotension (30%)
- Loss of appetite (55%)
- Malaise (50%)
- Myalgia (45%)
- Nausea (55%)
- Seizures (20%)
- Shock (12%)
- Tachycardia (60%)
- Arthralgia (25%)
- Back pain (20%)
- Sore throat (25%)
- Swollen lymph nodes (20%)

## Transmission

- Close contact (Primary route)
- Droplet transmission (Primary route)
- Respiratory droplets (Primary route)
- Nasopharyngeal carriage
- Respiratory Secretions

## Overview

Severe bacterial infection of the membranes surrounding the brain and spinal cord.

## Overview

Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis, a gram-negative diplococcus with 13 serogroups, of which 6 cause nearly all disease: A, B, C, W, X, and Y. Transmission occurs via respiratory droplets and close contact (kissing, shared utensils, crowded living). Asymptomatic nasopharyngeal carriage rate is 5–10% (up to 25% in adolescents). The bacterium can invade the bloodstream causing meningococcemia and/or cross the blood-brain barrier causing meningitis. The disease can progress from first symptoms to death within 24 hours, making it one of the most feared bacterial infections. Case fatality: 10–15% even with optimal treatment; up to 50% in meningococcemia with purpura fulminans.

## Emergency Signs

MEDICAL EMERGENCY — seek care IMMEDIATELY (minutes count):

- Non-blanching petechial or purpuric rash (do the glass test: press a glass tumbler against rash — if spots do NOT fade, call emergency services)

- Severe headache with neck stiffness and high fever

- Photophobia (light hurting the eyes) with fever

- Altered consciousness: confusion, drowsiness, difficult to wake

- Seizures

- Cold hands and feet with fever (circulatory compromise)

- Rapid breathing or difficulty breathing

- In babies: bulging fontanelle, high-pitched or moaning cry, pale/blotchy skin, refusing to feed, stiff body or floppy/unresponsive

## Detailed Symptoms

Incubation: 2–10 days (typically 3–4 days). Clinical presentations:

**Meningococcal meningitis (most common form, ~50% of cases):**

- Sudden onset severe headache

- High fever, neck stiffness (nuchal rigidity), photophobia — classic meningeal triad

- Nausea and vomiting (often projectile)

- Altered mental status: confusion → drowsiness → coma

- Kernig sign (inability to extend knee when hip flexed) and Brudzinski sign (neck flexion causes hip/knee flexion)

- Seizures (20–30%, especially in children)

- In infants: irritability, bulging fontanelle, poor feeding, high-pitched cry (classic signs may be absent)

**Meningococcemia (septicemia — ~40% of cases, may occur with or without meningitis):**

- Rapid onset fever with rigors

- **Petechial/purpuric rash:** Initially non-blanching petechiae → coalescing purpura → purpura fulminans (disseminated intravascular coagulation with hemorrhagic necrosis)

- **Glass test:** Press a clear glass against the rash — if it does NOT fade, suspect meningococcal septicemia → EMERGENCY

- Tachycardia, hypotension, cold extremities (circulatory collapse)

- Multi-organ failure in fulminant cases

- Limb ischemia (may require amputation in survivors)

**Fulminant course:** Can progress from first symptom to death in <12–24 hours.

## Course of Disease

**Typical disease course:**

1. **Incubation period:** 2–10 days (average 3–4 days).
2. **Prodromal phase (hours):** Upper respiratory symptoms, fever, headache — often indistinguishable from viral illness. **Critically, this phase may be very brief.**
3. **Acute meningitis (hours to 1–2 days):** High fever, severe headache, neck stiffness, photophobia, vomiting. Kernig and Brudzinski signs. Altered consciousness.
4. **Meningococcemia (may occur with or without meningitis):** Petechial rash → purpura → purpura fulminans. Hypotension, tachycardia, DIC. Can progress from first symptom to death within 12–24 hours.
5. **Resolution with treatment:** Antibiotics (ceftriaxone/cefotaxime) should be given within 1 hour of clinical suspicion. Dexamethasone as adjunct.

**Critical feature:** Fulminant meningococcal septicemia can progress from apparent good health to death within 12–24 hours. The non-blanching petechial rash is a red-flag sign requiring immediate emergency care.

## Diagnosis

Meningococcal disease is a medical emergency — do NOT delay treatment for diagnostics.

- **Blood cultures:** Obtain BEFORE antibiotics if possible (positive in 40–70%)

- **Lumbar puncture (when safe):** CSF shows: elevated WBC (polymorphonuclear predominance), elevated protein, decreased glucose, gram-negative diplococci on Gram stain (60–90% sensitivity)
  – Contraindicated if: signs of raised ICP, coagulopathy, cardiorespiratory compromise, local skin infection

- **CSF/blood PCR:** Most sensitive (>90%); can detect N. meningitidis even after antibiotic administration

- **Latex agglutination:** Rapid serogroup identification from CSF

- **Complete blood count:** Leukocytosis or leukopenia (poor prognosis if leukopenic); thrombocytopenia; elevated CRP/procalcitonin

- **Coagulation panel:** DIC screen (prolonged PT/aPTT, elevated D-dimer, low fibrinogen) — critical in meningococcemia

- **Skin biopsy of petechiae:** Can confirm diagnosis even after antibiotics

**Critical rule:** If meningococcal disease suspected → give parenteral antibiotics IMMEDIATELY, then investigate.

## Treatment

**IMMEDIATE TREATMENT IS LIFE-SAVING. Minutes matter.**

**Pre-hospital (GP/clinic):**

- Intramuscular benzylpenicillin (or ceftriaxone) IMMEDIATELY upon clinical suspicion, before transfer to hospital

**Hospital treatment:**

- **First-line:** Ceftriaxone 2 g IV every 12 hours (or cefotaxime 2 g IV every 4–6 hours) × 7 days

- **Penicillin-susceptible confirmed:** Benzylpenicillin IV may be used

- **Adjunctive dexamethasone:** 0.15 mg/kg IV every 6 hours × 4 days — give before or with first antibiotic dose; reduces mortality and neurological sequelae in bacterial meningitis (de Gans 2002 NEJM)

**Meningococcal septicemia (aggressive resuscitation):**

- Aggressive IV fluid resuscitation (may need 40–60 mL/kg in first hour)

- Vasopressor support (noradrenaline first-line)

- Fresh frozen plasma, platelets if DIC present

- ICU admission; may require ventilation, renal replacement therapy

- Activated protein C was used historically but no longer recommended

**Chemoprophylaxis for close contacts:**

- Ciprofloxacin 500 mg PO single dose (adults) or rifampicin 600 mg BID × 2 days

- Give to household contacts, kissing contacts, healthcare workers with unprotected direct exposure to secretions

- Administer within 24 hours of case identification

## Prevention Details

**Vaccination:**

- **Meningococcal ACWY conjugate vaccine (MenACWY — Menveo, Nimenrix, MenQuadfi):** Conjugate vaccines provide T-cell dependent immunity (longer lasting than polysaccharide). Single dose; booster every 5 years if ongoing risk. Licensed from age 2 months (varies by product).

- **Meningococcal B vaccine (MenB — Bexsero, Trumenba):** Covers serogroup B (common in Europe, Americas). 2-dose schedule. Not combined with ACWY.

- **Meningococcal polysaccharide (MPSV4):** Older vaccine; less immunogenic; no longer preferred

- **Pentavalent ACYWX:** In development; critical for Africa where serogroup X is emerging

- **MenAfriVac (conjugate A):** Single dose; eliminated serogroup A epidemics in Africa's meningitis belt since 2010 (one of the greatest vaccine successes)

**Travel-specific requirements:**

- **Hajj/Umrah (Saudi Arabia):** Meningococcal ACWY vaccination REQUIRED for visa; must be given ≥10 days before arrival

- **Meningitis belt travel (Sahel):** MenACWY recommended, especially during dry season (December–June)

- **College students living in dormitories:** MenACWY + consider MenB

**Outbreak response:** WHO threshold: 10 cases/100,000/week for 2 consecutive weeks → mass vaccination campaign.

## Travel Advice

Risk to travelers:

- **High risk:** Sub-Saharan Africa meningitis belt during dry season (December–June); Hajj/Umrah pilgrimage; crowded mass gatherings

- **Moderate risk:** Backpackers and youth travelers in shared accommodation (hostels, dormitories)

- **MenACWY vaccine required:** Hajj/Umrah visa (Saudi Arabia mandates it)

- **MenACWY vaccine recommended:** Travel to meningitis belt, prolonged close contact with local populations, healthcare workers in outbreak settings

- Carry a meningococcal vaccination certificate when traveling to Saudi Arabia or affected countries

- Seek immediate medical care for fever + non-blanching rash — this is a life-threatening emergency

- Serogroup B vaccine additionally recommended for prolonged stays in settings with known serogroup B activity (some European countries)

- Vaccination does not cover all serogroups — maintain awareness of symptoms regardless

## How common is it?

Global burden: WHO estimates 1.2 million cases and 135,000 deaths annually (2019 pre-COVID). Epidemiology varies by serogroup and region:

- **Africa meningitis belt** (26 countries from Senegal to Ethiopia): Historically devastating serogroup A epidemics during dry season (December–June)

- MenAfriVac introduction (2010) eliminated serogroup A epidemics — now serogroups C, W, and X are emerging

- **Europe/Americas:** Serogroups B, C, W, Y predominant

- outbreaks in universities, military

- serogroup W increasing

- **Asia:** Variable

- serogroup A (India, China), B, C, W

- underreported

- **Middle East:** Hajj-associated outbreaks historically drove global spread (2000 Hajj W135 epidemic)

- **Age distribution:** Bimodal — infants (<1 year: highest incidence) and adolescents/young adults (15–25: high carriage rate)

- **Risk factors:** Crowded living (dorms, barracks, Hajj), complement deficiency, asplenia, HIV, active/passive smoking, preceding viral URI

## Risk Factors

Travel to the African meningitis belt (sub-Saharan Africa), Hajj pilgrimage, living in close quarters (dormitories, military barracks), complement deficiency or asplenia, adolescents and young adults (15–24 years), infants under 1 year, exposure during outbreaks.

## Complications Details

Meningococcal disease carries severe morbidity even with optimal treatment:

- **Mortality:** 10–15% with treatment

- up to 50% in fulminant meningococcemia

- death can occur within hours

- **Limb amputation:** Purpura fulminans causes ischemic necrosis of extremities

- 10–20% of survivors require amputation of fingers, toes, or limbs

- **Hearing loss:** 5–10% of meningitis survivors

- may be bilateral and profound

- cochlear implant may be needed

- **Neurological sequelae (10–20%):** Cognitive impairment, seizure disorder, motor deficits, hydrocephalus, cranial nerve palsies

- **Skin scarring:** Extensive necrotic skin lesions requiring grafting

- **Adrenal hemorrhage (Waterhouse-Friderichsen syndrome):** Bilateral adrenal infarction → acute adrenal insufficiency

- high mortality

- **Renal failure:** From shock, DIC, and myoglobin deposition

- **Psychological impact:** PTSD, anxiety, depression in survivors and families

- **Arthritis:** Reactive arthritis in 5–10% during convalescence (immune-mediated)

- **Long-term disability:** Up to 40% of survivors have at least one residual disability

## Recovery & Outlook

**With treatment:** CFR 8–15% (meningitis), 20–40% (meningococcemia/septicemia).

**Without treatment:** Nearly 100% fatal.

**Sequelae in survivors:**

- Hearing loss: 5–10%.

- Neurological deficits: 10–20% (cognitive impairment, seizures, motor deficits).

- Limb amputation (due to purpura fulminans/DIC): 5–10% of meningococcemia survivors.

- Renal injury, adrenal hemorrhage (Waterhouse-Friderichsen syndrome).

**Prognostic factors:** Age <1 year or >60 years, rapid progression, meningococcemia without meningitis, DIC, and coma predict poor outcomes.

**Recovery:** Survivors without major sequelae typically recover fully within 2–4 weeks.

## Available Vaccines

- [Meningococcal ACWY Vaccine](https://medova.health/en/knowledge/vaccines/meningococcal-acwy-vaccine)
- [Meningococcal B](https://medova.health/en/knowledge/vaccines/meningococcal-b)

## Sources & content verification

- Data sources: WHO/ICD-11, CDC Yellow Book 2024, ECDC (SafeTripVax QMR-004, 2026-03-23), WHO Disease Factsheets 2024 + CDC Travelers' Health 2024 + Heymann CDD 21st ed., WHO Disease Factsheets 2024, CDC Yellow Book 2024, WHO Disease Factsheets 2024 + CDC Yellow Book 2024 + Heymann CDD 21st ed.
- Generated by: AI + Human review
- Review status: Awaiting medical review
- Last updated: 2026-03-29
- [www.who.int](https://www.who.int/emergencies/disease-outbreak-news)
- [www.who.int](https://www.who.int/news-room/fact-sheets)

---

The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.

[Full terms of use](https://medova.health/en/terms)